Tests KIVU-107 in adults with advanced solid tumors
Tests KIVU-107, a targeted drug, for safety in adults with advanced solid tumors.
Plain-language title generated from the registry record
Registry title: A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Key facts
- Where
- Adelaide, Brisbane, Camperdown, Geelong, and Sydney, AustraliaSee the 5 sites
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced or metastatic solid tumors that resisted standard therapy or have no standard therapy. It tests the safety of KIVU-107.
- Age
- 18 years or older
- Sex
- Men and women can join
- Disease stage
- Advanced or metastatic solid tumor, proven by tests of the tumor tissue. It resisted standard therapy or has no standard therapy. The disease must be measurable by RECIST v1.1.
- Earlier treatment
- No therapy of proven efficacy exists for the tumor. Cannot have had an antibody-drug conjugate (ADC) with a topoisomerase 1 inhibitor payload, or any PTK7-targeted therapy.
Main reasons for not taking part
- Prior ADC with a topoisomerase 1 inhibitor payload
- Any PTK7-targeted therapy
- Uncontrolled cardiovascular disease
- Active Hepatitis B, Hepatitis C, or HIV infection
- History of interstitial lung disease
Read by machine on 9 November 2026.
Where in Australia
- Adelaide, South AustraliaHospital not named in the registryTaking people
- Brisbane, QueenslandHospital not named in the registryTaking people
- Camperdown, New South WalesHospital not named in the registryTaking people
- Geelong, VictoriaHospital not named in the registryTaking people
- Sydney, New South WalesHospital not named in the registryTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Kivu Bioscience Inc.
- Trial code
- NCT07229313
- Record updated
- 24 September 2026
- Original description
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.Read full original descriptionShow less
A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Inclusion: Male or female ≥18 years of age; No therapy of proven efficacy exists for the tumor; Pathologically or histologically documented diagnosis of advanced / metastatic solid tumor malignancy that is resistant to standard therapy or for which no standard therapy is available; Adequate bone marrow, kidney, and liver function; Measurable disease using RECIST v1.1; ECOG 0 or 1; Life expectancy ≥ 3 months.
Exclusion: Prior treatment with any ADC with topoisomerase 1 inhibitor payload; Any PTK7 - targeted therapy; Uncontrolled cardiovascular disease; Active Hepatitis B, Hepatitis C, or HIV infection; History of interstitial lung disease; Major surgery, radiation therapy, or systemic anti-cancer within 3 weeks of study treatment start.